Compare UMH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMH | MLTX |
|---|---|---|
| Founded | 1968 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | UMH | MLTX |
|---|---|---|
| Price | $14.96 | $17.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $17.75 | ★ $27.50 |
| AVG Volume (30 Days) | 656.4K | ★ 834.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.51 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $203.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.93 | $5.95 |
| 52 Week High | $17.44 | $62.75 |
| Indicator | UMH | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.86 | 50.43 |
| Support Level | $14.71 | $15.50 |
| Resistance Level | $15.51 | $19.16 |
| Average True Range (ATR) | 0.29 | 0.97 |
| MACD | -0.10 | 0.12 |
| Stochastic Oscillator | 6.69 | 32.46 |
UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.